Alliancebernstein L.P. Cullinan Oncology, Inc. Transaction History
Alliancebernstein L.P.
- $287 Billion
- Q3 2024
A detailed history of Alliancebernstein L.P. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,854,410 shares of CGEM stock, worth $25.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,854,410
Previous 1,728,545
7.28%
Holding current value
$25.7 Million
Previous $30.1 Million
2.98%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$106 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$79.7 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$49.2 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$47.3 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$45.5 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $632M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...